Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn’s disease patients treated with infliximab
- 28 August 2020
- journal article
- editorial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 52 (6) , 1080-1081
Abstract
LINKED CONTENTThis article is linked to Bertani et al papers. To view these articles, visit https://doi.org/10.1111/apt.15870 and https://doi.org/10.1111/apt.16031Keywords
This publication has 8 references indexed in Scilit:
- Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximabAlimentary Pharmacology & Therapeutics, 2020
- Elevated Pretreatment Plasma Oncostatin M Is Associated With Poor Biochemical Response to InfliximabCrohn's & Colitis 360, 2019
- Targeting mucosal healing in Crohn’s disease: what the clinician needs to knowTherapeutic Advances in Gastroenterology, 2019
- The oncostatin M‐stromal cell axis in health and diseaseScandinavian Journal of Immunology, 2018
- Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel diseaseNature Medicine, 2017
- Host–microbe interactions have shaped the genetic architecture of inflammatory bowel diseaseNature, 2012
- Onconstatin M, a multifunctional cytokine2003
- Oncostatin M is a member of a cytokine family that includes leukemia-inhibitory factor, granulocyte colony-stimulating factor, and interleukin 6.Proceedings of the National Academy of Sciences, 1991